- Home
- CSQ vs LGND Comparison
CSQ vs LGND Comparison
Compare CSQ & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CSQ | LGND |
|---|---|---|
| Founded | 2003 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.7B |
| IPO Year | 2004 | 1997 |
Fundamental Metrics
Financial Performance| Metric | CSQ | LGND |
|---|---|---|
| Price | $20.73 | $284.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $256.29 |
| AVG Volume (30 Days) | 165.5K | ★ 175.5K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 7.53% | N/A |
| EPS Growth | N/A | ★ 2886.36 |
| EPS | N/A | ★ 1.63 |
| Revenue | N/A | ★ $141,102,000.00 |
| Revenue This Year | N/A | $1.25 |
| Revenue Next Year | N/A | $19.41 |
| P/E Ratio | ★ N/A | $174.29 |
| Revenue Growth | N/A | ★ 29.48 |
| 52 Week Low | $16.41 | $161.82 |
| 52 Week High | $21.15 | $326.63 |
Technical Indicators
Market Signals| Indicator | CSQ | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 51.28 | 45.03 |
| Support Level | $20.49 | $179.99 |
| Resistance Level | $21.15 | $317.49 |
| Average True Range (ATR) | 0.24 | 8.56 |
| MACD | -0.01 | -0.73 |
| Stochastic Oscillator | 41.55 | 34.24 |
Price Performance
Historical ComparisonAbout CSQ Calamos Strategic Total Return
Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.